Dan Dearborn
Executive VP of Finance & CFOMr. Dan Dearborn, C.P.A., is Chief Financial Officer of Tuhura Biosciences, Inc (formerly known as Morphogenesis, Inc) since 2018 and serves as its Executive Vice President of Finance. He is a CPA with finance experience exclusively with health care and biotechnology companies. From 2015 to 2017 Mr. Dearborn was CFO at MYMD Pharmaceuticals, an emerging biotechnology firm. Earlier, Mr. Dearborn served as CFO of Welldyne, Inc, a pharmacy benefit Manager that also had several related health care businesses and employed four hundred associates in Florida and Colorado. During his time with Welldyne, the company was sold to Carlyle, one of the largest private equity firms. From 2007 to 2015, he was at BioDelivery Sciences International as Controller. During his time at BDSI, the company signed two very large commercial Partnership agreements and was listed on NASDAQ. From 1997 until 2007, he was with Pharmerica, a long-term care pharmaceutical company. Mr. Dearborn is an alumnus of Loyola University in Maryland and joined Ernest & Young early in his career.
Positions
- Company NameTuHURA Biosciences, Inc.Stock CodeHURAPositionExecutive VP of Finance & CFO
